Sadiqa Mahmood is currently the general manager and senior vice president of the life sciences business at Health Catalyst, which aims to be "the catalyst for massive, measurable, data-informed healthcare improvement."
She is a dental surgeon with a master’s degree from the Harvard School of Public Health, and her distinguished career includes work at the Dana-Farber Cancer Institute, Partners HealthCare System, and the Boston Medical Center.
Health Catalyst has seen her spearhead tremendous growth in 18 months, with a customer base including regulators, top five contract research organizations, and top 40 biopharma groups.
Mahmood’s past achievements include overseeing the $104.5 million acquisition of the patient engagement platform Twistle.
At Dana Farber, she expanded an analytics program to executive leadership and front-line staff in several departments. Her help in developing a safety tool identifying high-risk patients on immunotherapy drugs led to the prevention of three hospital admissions per week. At Partners, she expanded a clinical collaboration program from five departments to 21 departments, tangibly improving clinical care.
Dr. Mahmood has lived and worked in Asia, the United Kingdom, and the United States of America. Currently, she travels between Boston, Massachusetts, and Houston, Texas. She is also a Formula One fan and races as a member of a local team.
"I grew up in a family of doctors and engineers, which influenced my decision to become a physician," she said in her acceptance speech. "I learned early on that human life can only be improved through research and innovation. That's why I made clinical innovation the core of my career so I can contribute to the discovery of new drugs, and new treatment options for people across the globe who need them and do not have those possibilities available. I've worked in healthcare systems that are incredibly different and complex. I have invested time in learning care delivery, technology policy, and the environment. Public health needs healthcare access, drug development, and cultural aspects of these systems. I find this complexity integrating."
